Levy, Mark L. http://orcid.org/0000-0002-1807-3246
Funding for this research was provided by:
AstraZeneca (ESR-19-20012)
Article History
Received: 21 August 2020
Accepted: 7 December 2020
First Online: 29 January 2021
Competing interests
: M.L.L. reports personal fees from Teva, Astra Zeneca, Novartis, non-financial support and other from GINA, personal fees from Chiesi, grants from Conzorcio Futuro In Ricerca, personal fees from Soar Beyond, Orion Pharmaceuticals, Menarini pharmaceuticals, Napp Pharmaceuticals, GSK, personal fees from National Services for Health Improvement (a company providing services for general practices (Expert Nurse Reviews)), non-financial support from Asthma and COPD (Joint) Lead for Whole Systems Integrated Care (WSIC) North West London, personal fees from Trudel Pharmaceuticals, outside the submitted work. He is also Editor Emeritus of the <i>npj Primary Care Respiratory Medicine</i> but has no role nor influence in any decisions regarding publication.